Country Access Report
Nigeria maintains a highly restrictive national drug control regime: classical psychedelics and novel psychoactive tryptamines/phenethylamines are effectively prohibited for general use and only accessible in tightly controlled research settings. Medical and legally reimbursed access is limited to established medicines (e.g., ketamine as an anaesthetic), which are prescription-only and regulated by NAFDAC; there is no evidence of marketed esketamine (Spravato) registration or public reimbursement for psychedelic-assisted psychiatric care. Enforcement and criminal penalties for possession, trafficking or unauthorised use of psychotropic substances are severe under the NDLEA framework.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Currently classified as a strictly controlled substance under Nigeria's national drug control laws, with no authorized medical use outside of approved clinical research. Possession, trafficking and unauthorised use of psychotropic substances are criminalised under the National Drug Law Enforcement Agency (NDLEA) Act and subject to severe penalties. [1] [2]
Compound Access
Compound Access
No evidence of a NAFDAC marketing authorisation or registered Spravato (esketamine) product was found in the NAFDAC product registry; therefore esketamine is not an available, reimbursed treatment in routine Nigerian clinical care. Ketamine (racemic) injections are registered as prescription-only medicines in Nigeria and are available for anaesthesia/acute clinical use under NAFDAC oversight, but esketamine (the Janssen nasal spray marketed as Spravato) does not appear on NAFDAC listings and is not publicly documented as approved or covered by public insurance. [1] [2]
Compound Access
Ketamine hydrochloride is a registered, prescription-only medicine in Nigeria and is marketed/authorised for clinical use (principally as an anaesthetic); NAFDAC records show approved injectable ketamine products on the national registry. In practice, ketamine is available in public and private hospitals for anaesthesia and emergency medicine under standard medical regulation, but there is no established, publicly reimbursed program for ketamine-based psychiatric treatment (e.g., for treatment‑resistant depression) akin to structured, insured esketamine programs found in some other countries. Off-label psychiatric use would therefore occur on a case-by-case basis in private clinical practice (if practised) and is unlikely to be covered by public insurance; any such use must comply with medicine regulations and professional guidance. [1] [2]
Compound Access
Compound Access
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. While ibogaine occupies grey zones in some jurisdictions internationally, in Nigeria the NDLEA criminal framework offers no authorised, reimbursed medical pathway for ibogaine-assisted treatment. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (the principal active constituent in ayahuasca brews) fall under the NDLEA control regime and are not subject to any recognised, reimbursed medical programme in Nigeria. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline-containing cacti and purified mescaline are covered by Nigeria's psychotropic controls and are not legally available for medical reimbursement. [1] [2]
Compound Access
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Novel phenethylamine psychedelics (2C series and related compounds) are treated as illicit psychotropic substances under NDLEA enforcement. [1] [2]
Last updated 2 Mar 2026. Source links come from the medical access guide.